Crestline European Capital Solutions Fund II increases Denovo Health stake
Published
Manchester-based Denovo Health Group Limited, a dental group founded in 2024, recorded an increase in shares held by an existing investor in its latest confirmation statement (period ending 9 July 2026). The company operates by acquiring dental practices across the UK and offering a shared ownership scheme to practice owners, allowing them to maintain clinical and operational autonomy.
Crestline European Capital Solutions Fund II, SCSP increased its stake by 185 percent, moving from 13,803,782 shares to a total of 39,310,442 shares. This updated holding consists of 39,072,801 A1 Preferred Ordinary shares and 237,641 A1 Ordinary shares.
The cap table also includes Denovo Nominees Limited, which maintains its position with 5,762,533 shares. This shareholder was present on the register at the start of the period and saw no change to its holding.
The filing confirms the current ownership structure following the share issuance to Crestline European Capital Solutions Fund II, SCSP. No other shareholders exited or joined the company during this reporting window. The company continues its operations from its Manchester headquarters, focusing on the acquisition and clinical support of dental businesses.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| Increased | CRESTLINE EUROPEAN CAPITAL SOLUTIONS FUND II, SCSP | 39,310,442 | +185% | A1 PREFERRED ORDINARY 39,072,801 A1 ORDINARY 237,641 |
Current shareholders (2)
| Shareholder | Total shares | Share classes |
|---|---|---|
| CRESTLINE EUROPEAN CAPITAL SOLUTIONS FUND II, SCSP | 39,310,442 | A1 ORDINARY 237,641 A1 PREFERRED ORDINARY 39,072,801 |
| DENOVO NOMINEES LIMITED | 15,003,535 | A2 ORDINARY 7,666 A2 PREFERRED ORDINARY 1,455,700 B ORDINARY 21,003 B PREFERRED ORDINARY 13,419,166 C ORDINARY 100,000 |
Contact the editorial team at [email protected]